Johnson & Johnson company to distribute IMI's test in Canada:
This article was originally published in Clinica
Executive Summary
McNeil Consumer Healthcare, a Johnson & Johnson company, is to distribute International Medical Innovation (IMI)'s Cholesterol 1,2,3 test in Canada under an exclusive agreement. Toronto-based IMI says the product, a predictive test for coronary artery disease, is the first noninvasive test in the world to use skin cholesterol to assess coronary artery disease risk.